ClinicalTrials.gg

Program

1100 ppm as MFP

Its studies are led by Procter and Gamble.

Furthest: phase 4, since Feb 9, 20212 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Procter and Gamble20 open or runningphase 4since Feb 9, 2021Feb 9, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2021First study: phase 4 study in CariesFirst studyNCT04763044 · 15 enrolled · United States
  2. Dec 11, 2024Phase 1 study in CariesNCT06735235 · 27 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06735235Caries · United States1CompletedJul 29, 202127
NCT04763044Caries · United States4CompletedJul 21, 202115

How it is read

Names in the registry

  • “1100 ppm as MFP”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.